Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S L Briggs

Showing results (21-30 of 32) with videos related to

Pageof 4
Sort By:
Cancer Research|July 15, 1992
Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27M Schrappe, T F Bumol, L D Apelgren, et al.
Bioconjugate Chemistry|July 1, 1992
In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigenJ J Starling, R S Maciak, N A Hinson, et al.
Cancer Research|September 1, 1993
Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft modelsD L Meyer, L N Jungheim, K L Law, et al.
The Journal of Biological Chemistry|June 6, 2000
Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolutionL Jin, S L Briggs, S Chandrasekhar, et al.
Protein Science : a Publication of the Protein Society|July 1, 1997
The crystal structure of human alpha-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitorN Y Chirgadze, D J Sall, V J Klimkowski, et al.
Journal of Medicinal Chemistry|March 1, 1989
New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activityB C Laguzza, C L Nichols, S L Briggs, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 2. Exploring interactions at the proximal (S2) binding siteD J Sall, S L Briggs, N Y Chirgadze, et al.
Bioconjugate Chemistry|March 1, 1993
Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructsL D Apelgren, D L Bailey, S L Briggs, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 1999
The design of potent, selective, non-covalent, peptide thrombin inhibitors utilizing imidazole as a S1 binding elementM R Wiley, L C Weir, S L Briggs, et al.
Nature|May 8, 1997
Crystal structure of the obese protein leptin-E100F Zhang, M B Basinski, J M Beals, et al.
Pageof 4

Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
Cancer Research|July 15, 1992
Long-term growth suppression of human glioma xenografts by chemoimmunoconjugates of 4-desacetylvinblastine-3-carboxyhydrazide and monoclonal antibody 9.2.27M Schrappe, T F Bumol, L D Apelgren, et al.
Bioconjugate Chemistry|July 1, 1992
In vivo antitumor activity of a panel of four monoclonal antibody-vinca alkaloid immunoconjugates which bind to three distinct epitopes of carcinoembryonic antigenJ J Starling, R S Maciak, N A Hinson, et al.
Cancer Research|September 1, 1993
Site-specific prodrug activation by antibody-beta-lactamase conjugates: regression and long-term growth inhibition of human colon carcinoma xenograft modelsD L Meyer, L N Jungheim, K L Law, et al.
The Journal of Biological Chemistry|June 6, 2000
Crystal structure of human parathyroid hormone 1-34 at 0.9-A resolutionL Jin, S L Briggs, S Chandrasekhar, et al.
Protein Science : a Publication of the Protein Society|July 1, 1997
The crystal structure of human alpha-thrombin complexed with LY178550, a nonpeptidyl, active site-directed inhibitorN Y Chirgadze, D J Sall, V J Klimkowski, et al.
Journal of Medicinal Chemistry|March 1, 1989
New antitumor monoclonal antibody-vinca conjugates LY203725 and related compounds: design, preparation, and representative in vivo activityB C Laguzza, C L Nichols, S L Briggs, et al.
Bioorganic & Medicinal Chemistry Letters|January 5, 1999
Dibasic benzo[b]thiophene derivatives as a novel class of active site directed thrombin inhibitors. 2. Exploring interactions at the proximal (S2) binding siteD J Sall, S L Briggs, N Y Chirgadze, et al.
Bioconjugate Chemistry|March 1, 1993
Chemoimmunoconjugate development for ovarian carcinoma therapy: preclinical studies with vinca alkaloid-monoclonal antibody constructsL D Apelgren, D L Bailey, S L Briggs, et al.
Bioorganic & Medicinal Chemistry Letters|October 6, 1999
The design of potent, selective, non-covalent, peptide thrombin inhibitors utilizing imidazole as a S1 binding elementM R Wiley, L C Weir, S L Briggs, et al.
Nature|May 8, 1997
Crystal structure of the obese protein leptin-E100F Zhang, M B Basinski, J M Beals, et al.
Pageof 4